Compugen Ltd. (CGEN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Compugen Ltd. (CGEN:NASDAQ), powered by AI.

Current Price
$2.04
P/E Ratio
5.4
Market Cap
191M
Sector
Healthcare
What is the Compugen Ltd. stock price forecast?

Compugen Ltd. is currently trading at $2.04. View real-time AI analysis on Alpha Lenz.

What is Compugen Ltd. insider trading activity?

View the latest insider trading data for Compugen Ltd. on Alpha Lenz.

What is Compugen Ltd.'s P/E ratio?

Compugen Ltd.'s P/E ratio is 5.4.

Compugen Ltd.

NASDAQ · CGEN
$2.04+0.00(+0.00%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Compugen Ltd.'s future dividend policy...
Alpha Chat Insight

Compugen Ltd. trades at a P/E of 5.4 (undervalued) with strong ROE of 44.8%. 3Y revenue CAGR of 113.3% highlights clear growth momentum.

Ask for details

Company Overview

Compugen Ltd. is a pioneering biotechnology company focused on the discovery and development of novel therapeutics for cancer immunotherapy. The company employs a unique predictive computational discovery platform that leverages extensive biological data to identify new drug targets and biomarkers, helping to streamline the traditionally complex and lengthy drug development process. As a leader in precision medicine, Compugen Ltd. specializes in immuno-oncology, an advanced field that aims to harness the body's immune system to combat cancer more effectively. The company's innovative approach has positioned it as an influential figure in the biotech industry, collaborating with leading pharmaceutical companies to bring cutting-edge cancer treatments to market. Based in Israel with additional operations in the United States, Compugen Ltd. plays a critical role in advancing healthcare by focusing on precision therapeutics that address the specific needs of patients.

CEODr. Eran Ophir Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees74

Company Statistics

FY 2025

Profile

$190.59MMarket Cap
$72.76MRevenue
0.00Shares Out
74Employees

Margins

87.29%Gross
44.13%EBITDA
43.05%Operating
48.65%Pre-Tax
48.57%Net

Valuation

5.39P/E
1.86P/B
2.62EV/Sales
3.21EV/EBITDA
6.08P/FCF

Growth (CAGR)

113.28%Rev 3Yr
105.20%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

26.03%ROA
44.84%ROE
23.07%ROIC

Financial Health

$90.60MCash & Cash Equivalents
$-36.76MNet Debt
52.41%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Compugen Ltd. (ticker: CGEN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 74 employees. Market cap is $191M.

The current price is $2.04 with a P/E ratio of 5.39x and P/B of 1.86x.

ROE is 44.84% and operating margin is 43.05%. Annual revenue is $73M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Compugen Ltd. (CGEN) Stock Forecast 2026 $2.04 — Price, Financials & Analyst Targets | Alpha Lenz